deafening silence, page-30

re: again If people put a bit of private research into sen (at least by ringing the new and very approachable Investor Relations guy), rather than use HC as their sole analysis, they would realise the company has admirable business health. There is no debt, the R&D is intelligent and progressive, the management are diverse in qualification and skills, Forecasts are stable and aggressive, the product is elite globally, and partners are now diverse also.

123enen, the credit you give regarding the Ecrypt sale is justified. Most would not have known it existed, let alone have any value, yet they pulled a listing onto AIM and licensing payments. Everyone knocks FG, but could they do better ?